Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Journal Information
Full Title: Ther Adv Psychopharmacol
Abbreviation: Ther Adv Psychopharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pharmacology & Pharmacy
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest statement: The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author was until 2020 an employee of Institute de recherche Servier and participated in the discovery, characterization, and development of agomelatine for the treatment both of major depression and GAD. This review was written upon invitation by the Institute International de recherche de Servier, from whom the author received financial compensation."
"Funding: The author received no financial support for the research, authorship, and/or publication of this article."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025